{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=68&state=Michigan",
    "query": {
      "state": "Michigan",
      "city": "Detroit",
      "page": 68
    },
    "page_size": 10
  },
  "pagination": {
    "page": 68,
    "page_size": 10,
    "total_count": 7248,
    "total_pages": 725,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=69&state=Michigan&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=67&state=Michigan&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T13:51:22.099Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04166318",
      "title": "Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anal Basaloid Carcinoma",
        "Anal Canal Cloacogenic Carcinoma",
        "Anal Canal Squamous Cell Carcinoma",
        "Anal Margin Squamous Cell Carcinoma",
        "Stage I Anal Cancer AJCC v8",
        "Stage IIA Anal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mitomycin",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2020-01-02",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-15T13:51:22.099Z",
      "location_count": 659,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04166318"
    },
    {
      "nct_id": "NCT05014646",
      "title": "Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smoldering Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Cholestyramine",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2022-03-07",
      "completion_date": "2027-01-16",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-11-15T13:51:22.099Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Detroit, Michigan • New York, New York + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05014646"
    },
    {
      "nct_id": "NCT04342897",
      "title": "A Study of LY3127804 in Participants With COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Pneumonia"
      ],
      "interventions": [
        {
          "name": "LY3127804",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2020-04-20",
      "completion_date": "2020-10-12",
      "has_results": true,
      "last_update_posted_date": "2021-08-12",
      "last_synced_at": "2026-11-15T13:51:22.099Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04342897"
    },
    {
      "nct_id": "NCT04895410",
      "title": "Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Lemzoparlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2022-01-17",
      "completion_date": "2022-06-24",
      "has_results": false,
      "last_update_posted_date": "2023-03-06",
      "last_synced_at": "2026-11-15T13:51:22.099Z",
      "location_count": 12,
      "location_summary": "Miami, Florida • Tampa, Florida • Louisville, Kentucky + 9 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04895410"
    },
    {
      "nct_id": "NCT01270880",
      "title": "Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Hormone-resistant Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Hsp90 inhibitor STA-9090",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "enzyme-linked immunosorbent assay",
          "type": "OTHER"
        },
        {
          "name": "RNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "spectrophotometry",
          "type": "OTHER"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "GENETIC"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2011-01",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2018-09-18",
      "last_synced_at": "2026-11-15T13:51:22.099Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Detroit, Michigan • Piscataway, New Jersey + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Piscataway",
          "state": "New Jersey"
        },
        {
          "city": "Wisconsin Rapids",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01270880"
    },
    {
      "nct_id": "NCT00000796",
      "title": "A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Cycloserine",
          "type": "DRUG"
        },
        {
          "name": "Ethionamide",
          "type": "DRUG"
        },
        {
          "name": "Capreomycin sulfate",
          "type": "DRUG"
        },
        {
          "name": "Aminosalicylic acid",
          "type": "DRUG"
        },
        {
          "name": "Streptomycin sulfate",
          "type": "DRUG"
        },
        {
          "name": "Ethambutol hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Amikacin sulfate",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid",
          "type": "DRUG"
        },
        {
          "name": "Pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "Pyridoxine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Clofazimine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 525,
      "start_date": null,
      "completion_date": "1998-10",
      "has_results": false,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-11-15T13:51:22.099Z",
      "location_count": 21,
      "location_summary": "Chicago, Illinois • Detroit, Michigan • Brooklyn, New York + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000796"
    },
    {
      "nct_id": "NCT00977574",
      "title": "Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "Endometrial Adenosquamous Carcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Recurrent Malignant Uterine Corpus Neoplasm",
        "Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage",
        "Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage",
        "Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage",
        "Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage",
        "Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Ixabepilone",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 349,
      "start_date": "2009-09-14",
      "completion_date": "2027-03-06",
      "has_results": true,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-15T13:51:22.099Z",
      "location_count": 230,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 163 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00977574"
    },
    {
      "nct_id": "NCT00172120",
      "title": "Open Label Extension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "ALX1-11",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 91,
      "start_date": "2005-01-10",
      "completion_date": "2006-10-27",
      "has_results": false,
      "last_update_posted_date": "2021-05-17",
      "last_synced_at": "2026-11-15T13:51:22.099Z",
      "location_count": 9,
      "location_summary": "Beverly Hills, California • Chicago, Illinois • Detroit, Michigan + 6 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Bismarck",
          "state": "North Dakota"
        },
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00172120"
    },
    {
      "nct_id": "NCT04676724",
      "title": "Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "GSK3228836",
          "type": "DRUG"
        },
        {
          "name": "PegIFN",
          "type": "DRUG"
        },
        {
          "name": "NA therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 108,
      "start_date": "2021-01-28",
      "completion_date": "2023-02-17",
      "has_results": true,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-11-15T13:51:22.099Z",
      "location_count": 4,
      "location_summary": "Sacramento, California • Iowa City, Iowa • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04676724"
    },
    {
      "nct_id": "NCT03176459",
      "title": "Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "C-Section",
        "Pain Management"
      ],
      "interventions": [
        {
          "name": "Exparel + Bupivacaine",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 186,
      "start_date": "2017-06-01",
      "completion_date": "2018-12-04",
      "has_results": true,
      "last_update_posted_date": "2021-01-06",
      "last_synced_at": "2026-11-15T13:51:22.099Z",
      "location_count": 12,
      "location_summary": "Loma Linda, California • Stanford, California • Boston, Massachusetts + 7 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03176459"
    }
  ]
}